Differential effects of novel protamine variants on myocyte contractile function with left ventricular failure

Surgery

Volumn 121, Issue 3, 1997, Pages 304-313

  Cox, Monty H ^b   Seung Jun, O ^b   Clair, Mark J ^b   Mukherjee, Rupak ^b   Wakefield, Thomas W ^b   Andrews, Philip C ^b   Stanley, James C ^b   Crawford Jr , Fred A ^b   Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTAMINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; SWINE;

EID: 12644267269     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90359-7     Document Type: Article

References (44)

1. Schneidman D, Peebles R. Socio-economic fact book for surgery. Chicago: American College of Surgeons, 1991-1992:46-7.
2. Goldman BS, Joison J, Austen WG. Cardiovascular effects of protamine sulfate. Ann Thorac Surg 1969;7:459-71.
3. Gourin A, Streisand RL, Greineder JK, Stuckey JH. Protamine sulfate administration and the cardiovascular system. J Thorac Cardiovasc Surg 1971;62:193-204.
4. Jastrzebski J, Sykes MK, Woods DG. Cardiorespiratory effects of protamine after cardiopulmonary bypass in man. Thorax 1974;29:534-8.
5. Fadali MA, Ledbetter M, Papacostas CA, Duke LJ, Lemole GM. Mechanism responsible for the cardiovascular depressant effect of protamine sulfate. Ann Surg 1974;180:232-5.
6. Fadali MA, Papacostas CA, Duke JJ, Ledbetter M, Osbakken M. Cardiovascular depressant effect of protamine sulfate: experimental and clinical implications. Thorax 1976;31:320-3.
7. Green CE, Higgins CB, Kelley MJ, Schmidt WS, Haigler FH, Newell JD. Cardiovascular effects of protamine sulfate. Invest Radiol 1981;16:324-9.
8. Shapira N, Schaff HV, Piehler JM, White RD, Sill JC, Pluth JR. Cardiovascular effects of protamine sulfate in man. J Thorac Cardiovasc Surg 1982;84:505-14.
9. Sethna D, Gray R, Bussell J, Raymond M, Matloff J. Further studies on the myocardial metabolic effects of protamine sulfate following cardiopulmonary bypass. Anesth Analg 1982;61:476-7.
10. Michaels IA, Barash PG. Hemodynamic changes during protamine administration. Anesth Analg 1983;62:831-5.
11. Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985;64:348-61.
12. Alvarez J, Alvarez L, Escudero C, Gilsanz F, De Oya S, Castillo-Olivarez JL. Hemodynamic and morphologic alterations after experimental administration of protamine sulfate. Am J Surg 1988;155:735-40.
13. Del Re MR, Ayd JD, Schultheis LW, Heitmiller ES. Protamine and left ventricular function: a transesophageal echocardiography study. Anesth Analg 1993;77:1098-103.
14. Hird RB, Spinale FG, Hewett KW, Mukherjee R, Crawford FA. The direct effects of protamine sulfate on myocyte contractile processes. J Thorac Cardiovasc Surg 1994;108:1100-14.
15. Hird RB, Crawford FA, Mukherjee R, Zile MR, Spinale FG. Effects of protamine on myocyte contractile function and β-adrenergic responsiveness. Ann Thorac Surg 1994;57:1066-75.
16. Hird RB, Crawford FA, Spinale FG. Differential effects of protamine sulfate on myocyte contractile function with left ventricular failure. J Am Coll Cardiol 1995;25:773-80.
17. Hird RB, Wakefield TW, Mukherjee R, Jones BU, Crawford FA, Andrews PC, et al. The direct effects of protamine sulfate on myocyte contractile processes: cellular and molecular mechanisms. Circulation 1995;92:II-433-46.
18. DeLucia A, Wakefield TW, Andrews PC, Nichol BJ, Kadell AM, Wrobleski SK, et al. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal. J Vasc Surg 1993;18:49-60.
19. Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Fazzalari A, Nichol BJ, et al. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues. J Surg Res 1994;56:586-93.
20. Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Schmidt R, Tejwani S, et al. Effective and less toxic reversal of low-molecular-weight heparin anticoagulation by a designer variant of protamine. J Vasc Surg 1995;21:839-50.
21. Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Tejwani S, Julin MS, et al. A [+18RGD] protamine-variant for nontoxic and effective reversal of conventional heparin and low-molecular weight heparin anticoagulation. J Surg Res 1996;63:280-6.
22. Weintraub WS, Wenger NK, Jones EL, Craver JM, Guyton RA. Changing clinical characteristics of coronary surgery patients: differences between men and women. Circulation 1993;88:79-86.
23. Spinale FG, Mukherjee R, Fulbright BM, Hu J, Crawford FA, Zile MR. Contractile properties of isolated porcine ventricular myocytes. Cardiovasc Res 1993;27:304-11.
24. Mukherjee R, Crawford FA, Hewett KW, Spinale FG. Cell and sarcomere contractile performance from the same cardiocyte using video microscopy. J Appl Physiol 1993;74:2023-33.
25. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, et al. Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res 1992;71:174-87.
26. Tanaka R, Fulbright BM, Mukherjee R, Burchell SA, Zile MR, Spinale FG. The cellular basis for the blunted response to β-adrenergic stimulation in supraventricular tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1993;25:1215-33.
27. Steel RG, Torrie JH. Principles and procedures of statistics: a biomedical approach. New York: McGraw-Hill, 1980:172-553.
28. Burchell SA, Spinale FG, Crawford FA, Tanaka R, Zile MR. Effects of chronic tachycardia-induced cardiomyopathy on the β-adrenergic receptor system. J Thorac Cardiovasc Surg 1992;104:1006-12.
29. Wakefield TW, Lindblad B, Stanley TJ, Nichol BJ, Stanley JC, Bergqvist D, et al. Heparin and protamine use in peripheral vascular surgery: a comparison between surgeons of the Society for Vascular Surgery and the European Society for Vascular Surgery. Eur J Vasc Surg 1994;8:193-8.
30. Carver W, Terracio L, Borg TK. Cell-matrix interactions: matrix receptors in the development and maintenance of the heart. In: Eghbali-Webb M, editor. Molecular biology of collagen matrix in the heart. Austin: R G Landes Co, 1995:41-59.
31. Carver W, Terracio L. Integrins-mediated cell-matrix interactions in heart development and in disease. Heart Failure 1993;8:255-63.
32. Terracio L, Rubin K, Gullberg D, Balog E, Carver W, Jyring R, et al. Expression of collagen binding integrins during cardiac development and hypertrophy. Circ Res 1991;68:734-44.
33. Spinale FG. Pacing tachycardia-induced congestive heart failure. Heart Failure 1995;11:219-32.
34. 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
35. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. J Am Coll Cardiol 1993;22:146A-53A.
36. Lerman A, Kubo SK, Tschumperlin LK, Burnett JC. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992;20:849-53.
37. Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y, Carabello BA. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 1990;259:H218-29.
38. Zellner JL, Spinale FG, Eble DM, Hewett KW, Crawford FA. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res 1991;69:590-600.
39. +-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1992;24:277-94.
40. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, et al. The effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic mitral regurgitation. J Clin Invest 1994;93:2639-48.
41. Morel DR, Lowenstein E, Nguyenduy T, Robinson DR, Repine JE, Chenoweth DE, et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep: evidence for the role of reactive oxygen metabolites following nonimmunological complement activation. Circ Res 1988;62:905-15.
42. Conzen PR, Habazettl H, Gutmann R, Hobbhahn J, Goetz AE, Peter K, et al. Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs. Anesth Analg 1989;68:25-31.
43. Morel DR, Costabella PM, Pittet JF. Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin with protamine in awake sheep are infusion rate-dependent. Anesthesiology 1990;73:415-24.
44. Pearson PJ, Evora PR, Ayrancioglu K, Schaff HV. Protamine releases endothelium-derived relaxing factor from systemic arteries: a possible mechanism of hypotension during heparin neutralization. Circulation 1992;86:289-94.